Immuron Ltd. IMRN 深 滬
等待開盤 10-24 09:30:00 美东时间
2.1446
+0.055
+2.61%
華盛通- 最 高2.25
- 今 開2.25
- 成交量 3.05万股
- 最 低 2.11
- 昨 收 2.09
- 總市值 1228.56万
- 52周最高 2.483
- 市盈率 靜 --
- 換手率 0.53%
- 52周最低 1.50
- 委 比 71.63%
- 總股本 572.86万
- 歷史最高 28.99
- 量 比 0.40
- 振 幅 6.70%
- 歷史最低 1.39
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immuron Limited Issues New Shares, Ensures Compliance
An update from Immuron Limited ( ($AU:IMC) ) is now available. Immuron Limited ...
10-20 10:38
Immuron Q1 FY26 YoY growth
<p>Immunon Limited has reported ongoing sales growth for Travelan®, an over-the-counter immune supplement, with Q1 global sales reaching AUD$2.0 million, a 34% increase year-over-year. Australian sales led the growth at AUD$1.6 million, up 52%, driven by digital marketing, store expansion, and increased travel. US sales also rose 44% to AUD$0.4 million, boosted by improved Amazon presence and social media efforts. Canadian sales dropped 92% to AU...
10-13 10:00
Immuron Limited Reports Strong Q1 FY26 Sales Growth
An announcement from Immuron Limited ( ($AU:IMC) ) is now available. Immuron Li...
10-13 07:58
Immuron Expands ATM Offering to Boost Financial Resources
Immuron ( ($IMRN) ) has shared an announcement. On October 3, 2025, Immuron Lim...
10-03 22:17
Immuron Says It Is On Track To Exceed FY24 First-Quarter Sales; To Request End Of Phase 2 Meeting With FDA For IMM-124E
US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted
10-02 18:38
Immuron Limited Advances Clinical and Commercial Initiatives
Immuron Limited ( ($AU:IMC) ) just unveiled an update. Immuron Limited announce...
10-02 07:54
Immuron Limited Secures Auditor Consent for Financial Filings
Immuron ( ($IMRN) ) has issued an announcement. On September 30, 2025, Immuron ...
09-30 20:29
Immuron partners with InvestorHub
Immunot Limited has partnered with InvestorHub to launch an interactive investor hub, enhancing communication with shareholders and investors. The platform will feature regular updates, including videos, educational materials, and research. CEO Steven Lydeamore highlighted upcoming milestones: FDA submission and approval of IMM-529 IND and clinical trial results for Travelan®. The company focuses on developing orally administered antibodies for i...
08-27 02:29
Immuron Enhances Investor Engagement with New Interactive Hub
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited has p...
08-26 13:57
Immuron CEO to Present at Coffee Microcaps Conference
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited annou...
07-25 08:57
